Drugs / DS-7080a
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02530918 | Jul 2015 → Jan 2018 | diabetic macular edema, wet macular degeneration | Daiichi Sankyo | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DS-7080a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02530918 ↗ |
| Action | Activate | “Agonistic monoclonal antibody against Robo4” PMID 42064470 ↗ Jan 2026 |
| Modality | Monoclonal antibody | “agonistic monoclonal antibody against Robo4” PMID 42064470 ↗ Jan 2026 |
| Route | Intravitreal | “1.0, 2.0, or 4.0 mg administered by a 50 μL intravitreal (IVT) injection of solution” NCT02530918 ↗ |
| Target | ROBO4 | “agonistic monoclonal antibody against Robo4” PMID 42064470 ↗ Jan 2026 |